Purinergic Signaling and the Postmenopausal Heart
NCT06015776
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diastolic Heart Failure
- Heart Failure With Preserved Ejection Fraction
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 30 to 88 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Beth Israel Deaconess Medical Center
- Last updated on ClinicalTrials.gov
- March 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Beth Israel Deaconess Medical Center · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.